A Study to Investigate Safety of Belumosudil in Participants Aged 12 Years and Above, With Chronic Graft-versus-host Disease (cGVHD)

This is an interventional phase IV clinical study which is single-arm study for assessing the safety of belumosudil in Indian patients who are12 years and older. Study details include: * The study duration will be up to 12 months per participant. * The treatment duration will be up to 24 weeks. * The number of visits will be 7.

NCT Number	NCT07135973
Lead Sponsor	Sanofi
Conditions	Chronic Graft Versus Host Disease
Enrollment	26 participants
Start Date	2026-08-10
Primary Completion	2027-08-30 (estimated)
Study Completion	2028-03-17 (estimated)
Updated on ClinicalTrials.gov	2026-05-12